ArticleBMC oral health2025
Pulp response following direct pulp capping with Tideglusib and mineral trioxide aggregate: an animal study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Histological evaluation of pulpal healing following direct pulp capping with polytetrafluoroethylene or melatonin, with or without adjunctive low-level laser therapy in Wistar rat molars.Scientific reports · 2026Article
- Effect of Moringa oleifera leaf extract gel on pulp repair following pulpotomy: an in-vivo study.Scientific reports · 2026Article
- In Vitro Evaluation of Novel Resin-Modified Calcium Silicate Cements for Minimally Invasive Vital Pulp Therapy.International dental journal · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral biomaterials have been employed for direct pulp capping (DPC) with varying degrees of success. This study evaluated the pulp response following DPC with a new material developed from glycogen synthase kinase-3 inhibitors (Tideglusib) and mineral trioxide aggregate (MTA).
methodsClass V cavities with pulp exposure were conducted on 56 teeth in two adult male mongrel dogs. Based on the evaluation periods, these teeth were divided into two major groups at random (28 teeth/dog each). Groups A and B underwent histopathology evaluations three and eight weeks following DPC, respectively. Depending on the capping material used, each main group was further divided into two equal subgroups (14 teeth each). ProRoot white MTA was applied directly to the exposed vital pulps in subgroup 1. While subgroup 2's exposed pulps were immediately capped with resorbable collagen that had been soaked in a freshly made 50 nM Tideglusib drug solution. Glass ionomer filling was then used to seal the access cavities. Every specimen underwent histological evaluation and was scored according to the number of inflammatory cells, the disorganization of the pulp tissue, and the formation of calcific bridges. All data were statistically examined.
resultsIn both groups A and B, subgroup 2 showed a statistically significant increase in the number of inflammatory cells and pulp tissue disorganization compared to subgroup 1 (P < 0.05). In both groups A and B, there was no statistically significant difference in the formation of new hard tissue between subgroups 1 and 2 (P = 0.157).
conclusionWhen used as direct vital pulp capping materials in a dog model, Tideglusib causes more soft tissue disorganization and an inflammatory response inside the pulp cavity than ProRoot white MTA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.